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Abstract 
Cell responses to the extracellular matrix depend on specific signaling events. These are important 
from early development, through differentiation and tissue homeostasis, immune surveillance and 
disease pathogenesis. Signaling not only regulates cell adhesion cytoskeletal organisation and 
motility, but also provides survival and proliferation cues. The major classes of cell surface receptors 
for matrix macromolecules are the integrins, discoidin domain receptors and transmembrane 
proteoglycans such as syndecans and CD44. Cells respond not only to specific ligands, such as 
collagen, fibronectin or basement membrane glycoproteins, but also in terms of matrix rigidity. This 
can regulate the release and subsequent biological activity of matrix-bound growth factors, for 
example transforming growth factor-β. In the environment of tumours, there may be changes in cell 
populations and their receptor profiles as well as matrix constitution and protein cross-linking. Here 
we summarize roles of the three major matrix receptor types, with emphasis on how they function in 
tumour progression. 
 
 
1. Introduction 
 
Through the discovery of specific receptors for matrix glycoproteins, nearly three decades ago, began a 
process by which it was increasingly realized that extracellular matrix (ECM) could influence cellular 
events at a molecular level. Prior to that, it had been thought that the ECM was structurally important 
but that cells were responding to the physical environment but not the molecular environment. Now it 
is recognised that both elements are important; interactions between specific collagens and 
glycoproteins with receptors signal to the cell interior, generating control of the cytoskeleton, survival, 
differentiation and gene expression. In addition, physical forces, generated by cellular interactions 
with the ECM in turn can also influence proliferation and migration in normal tissues but are in the 
spotlight currently with respect to tumor stroma and progression.  
 
In this review, the focus is on three distinct receptor groups, the integrins, a major class of ECM 
receptor, the discoidin domain receptors (DDRs), receptors for collagens and a varied group of cell 
surface proteoglycans. Each class of receptor is widespread, and increasingly it is recognized they may 
contribute essential functions in normal development and homeostasis, but altered in the malignant 
state. Moreover, these three receptor classes often do not work in isolation, but in combination with 
each other and with other types of receptor, for example growth factor receptors. These can be part of 
complexes with integrins and syndecan proteoglycans, with examples being known for receptors for 
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epidermal growth factors, fibroblast growth factors, vascular endothelial growth factor and insulin-like 
growth factors. Other ECM receptors associate with cytokine and chemokine receptors, with 
implications for inflammation. 
 
2. Integrins and tumorigenesis 
 
Integrins are heterodimeric cell surface receptors that mediate interactions with the ECM and play an 
important role in the tumor microenvironment. Both α and β subunits are transmembrane proteins 
with the β subunit, in particular, linking to cytoskeletal and regulatory proteins (Figure 1). Prominent 
among the signaling molecules associated with integrins are focal adhesion kinase and the proto-
oncogene, Src [1, 2]. ECM ligands interact at the distal tip of the integrin dimers, and through signaling 
not only control cell adhesion, migration and actin cytoskeletal architecture, they are also a key 
component of anchorage-dependent survival mechanisms. Normal cells deprived of integrin-driven 
adhesion can enter anoikis and undergo cell death [3], a process often bypassed in the transformed 
cell. A further important property of integrins in many cells, notably leukocytes, is that they may exist 
in inactive, or low affinity conformations, or in extended, high affinity forms [4]. A key requisite for 
activation is the binding of talin to the cytoplasmic domain of the β subunit [4, 5].  Talin serves as an 
adapter molecule for other actin-associated proteins such as vinculin [6]. Low affinity conformers can 
be activated by a process of “inside-out” signaling deriving from other receptor signal cascades, e.g. 
growth factors [4]. 
 
Integrins are present on the surfaces of nearly all nucleated cells, and therefore are present on tumour 
cells, and in solid tumours, as well as in cells of the stroma. There have been several detailed recent 
reviews of integrin roles in tumour progression [7-11]. However, a major and important cell type 
within the stroma is the “cancer-associated fibroblast” (CAF) [12-14], which has received less attention 
and is the focus here. This term in fact describes a group of fibroblastic cells of different origin, some 
of which share characteristics with myofibroblasts in granulation tissue during wound healing and 
tissue fibrosis [15]. CAFs are the major producers of ECM in the tumour, but they are also involved in 
the dynamic re-organization and remodeling of the ECM, which affects proliferation, survival and 
migration of the tumour cells. The ECM also serves as a reservoir of growth factors and cytokines that 
take part in bidirectional communication that occurs between the stroma and the tumour cells [16, 17]. 
In addition, crosslinking and other factors affecting the stiffness of the ECM have been shown to affect 
tumour progression and invasion [18, 19].  Recent data also suggest the CAF-ECM interactions are 
involved in regulating the metastatic niche as well as chemoresistence [20].  
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2.1. Integrin expression on CAFs  
In vitro culture of fibroblasts changes the integrin repertoire. Integrins identified under in vitro 
conditions are, therefore, not necessarily the same as those of CAFs in vivo. Accumulated data from 
different types of fibroblasts have shown that integrins include the collagen-binding integrins α1β1, 
α2β1 and α11β1, the RGD -binding integrins α4β1, α4β7 (on lung fibroblasts), α5β1, α9β1, αvβ1, αvβ3, 
αvβ5 and αvβ8, and the laminin-binding integrin α3β1. Recent data from fibrosis models suggest that 
in some types of fibrosis a substantial fraction of the myofibroblasts are derived from perivascular 
pericytes [21, 22]. Therefore in the context of fibrosis or CAFs, the mesenchymally derived cell 
population called myofibroblasts constitutes a more heterogeneous cell mixture compared to resident 
tissue fibroblasts in a tissue. Furthermore, the balance between cells of different origins change during 
tissue regeneration/fibrosis. In some organs the main part of the fibrotic stroma is derived from a 
small pool of resident perivascular Gli1 expressing mesenchymal stem cells which during fibrotic 
reaction expands to become the major producers of ECM [23]. It is likely that similar dynamics exist for 
different CAF populations in the stroma.  
 
More work has been performed on myofibroblast integrins in relation to wound healing and fibrotic 
conditions than CAF integrins. In the fibrosis field integrin αvβ1 has recently received considerable 
attention following the findings that it is able to bind latency associated peptide (LAP) and thereby 
activate TGF-β [22], while blocking of αvβ1 function with a small molecule inhibitor was found to 
attenuate experimental liver and lung fibrosis [22]. In table 1 some available data on integrin 
expression in myofibroblasts and CAFs is presented.  
 
2.1.1. Collagen-binding integrins 
The α1 and α2 integrin chains have been described on dermal myofibroblasts, but data on their 
expression in CAFs are limited [34, 35]. In one histochemical study of colon adenocarcinomas α-
smooth muscle actin (α-SMA) positive, β-PDGFR negative stromal cells, expressed high levels of α1β1 
and α5β1 and some α2β1 [35].  In general, α1 and α2 integrin chains are widely expressed and can also 
be expressed in tumour cells as well as vascular and immune cells [36-38]. These integrins are 
therefore not particularly useful as biomarkers for the tumour CAFs. α10 integrin is normally restricted 
to cartilage and a very restricted subset of fibroblasts [39]. Curiously, melanoma cells have been 
reported to express α10, but to our knowledge no expression in CAFs has been reported [40]. α11β1 
integrin is expressed by different fibroblast types and is induced during myofibroblast differentiation 
[41-46]. Data from wound healing studies in mice demonstrate that α11 affects myofibroblast 
differentiation in the wound bed [41]. In collagen gels α11-mediated functions synergizing with TGF-β 
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were demonstrated to be dependent on JNK-signaling [41].  Recent data from mouse models of lung 
cancer show that α11 expression associated with increased stiffness of the tumours, suggesting that 
α11β1-mediated ECM reorganization occurred [42]. In addition to the direct effect of α11β1 taking 
part in collagen reorganization, a correlation with lysyl oxidase-like 1(LOXL1) expression was noted. 
This indirect mode of regulating collagen cross-linking enzyme levels needs further studies to directly 
link it to α11β1-mediated molecular mechanisms. Non-small cell lung cancers may express α11 in 
activated stroma, where it has the potential to be a biomarker for activated CAFs [47]. It will be 
important to determine if this α11 expression applies to CAFs in other tumours, or whether this is 
lung-specific. Recently the original xenograft experiments of lung cancer cells co-implanted with 
fibroblasts, with or without α11, has been validated in immunocompromised SCID mice deficient in 
α11 [42]. These experiments demonstrated an important role for α11 in the endogenous tumour 
stroma for tumour growth and metastasis [42]. Since α11β1 is restricted to the mesenchymally-
derived fibroblasts it may be that α11 is part of the gene signature in the leading, invading “ trailblazer” 
cells of metastasizing breast cancer cells [48]. siRNA knockdown of α11 in this experimental system 
reduced tumour cell invasion. 
 
Interestingly, fibroblast-specific deletion of the β1 integrin gene in mice, which leads to a loss of all 
collagen-binding integrin receptors (but also the 7 additional β1-containing integrin heterodimers), 
was found to interfere with myofibroblast differentiation during skin wound healing [49]. This was 
described to be due to a decreased activation of latent TGF-β. The exact mechanism behind this defect 
was not elucidated, but it would be interesting to examine these data in light of recent results 
obtained with integrin α11-/- mice [41] and αvβ1-blocking reagents [22]. 
 
2.1.2. EDA+ fibronectin-binding integrins 
The alternatively spliced, extra domain A containing (EDA+) fibronectin is a biomarker of activated 
fibroblasts in wound healing, fibrosis and tumour stroma [14, 15]. This fibronectin splice form is also 
expressed in neovasculature in regenerating tissues [50]. Several receptors have been suggested to 
bind EDA+ fibronectin in fibroblasts including α4β1 and α9β1 which bind at a cryptic site that is 
exposed only after proteolytic cleavage [51]. Separate from the binding of unknown CAF receptors to 
the EDA domain, the main fibronectin receptor on CAFs, α5β1, interacts with the RGD motif in the 10th 
fibronectin type III domain, and early work suggested that presence of EDA domain increased the 
affinity of α5β1 interaction [52]. In a classical paper, EDA+ fibronectin was shown to be required for 
TGF-β stimulated myofibroblast differentiation [53]. However, despite EDA+ fibronectin serving as a 
reliable biomarker for myofibroblasts, careful analysis of tumour stroma in a Rip-tag2 mice model of 
breast cancer did not support a role for EDA+ fibronectin in CAF activation or α-SMA expression [50]. 
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This is unlike the situation in lung and cardiac fibrosis where EDA+ fibronectin appears to regulate 
myofibroblast differentiation. In lung, a candidate for this effect is α4β7 integrin [27, whereas in the 
heart the receptor mediating this effect has not been characterized [54], although some data suggest 
that it might be an indirect mechanism dependent on recruitment of non-integrin toll like receptor-2- 
(TLR-2) expressing macrophages. The recent finding that the toll like receptor 4 (TLR-4) on 
inflammatory cells binds to EDA+ fibronectin  in the skin has suggested this receptor to be a at the core 
of a co-ordinating mechanism for inflammatory and fibrotic responses in keloids [55]. 
 
2.1.3. TGF-β activating integrins 
The αv-containing integrins αvβ1, αvβ3, αvβ5 and αvβ8 in a variety of fibroblasts and pericytes are 
reported to activate latent TGF-β by binding to the RGD motif of the latency-associated protein (LAP) 
that is bound to TGF-β and the latent TGF-β binding protein (LTBP) forming the large latent complex 
(LLC) [22, 56]. LTBP anchors the LLC firmly to the stretch-resistant ECM. Cell contraction then “cracks” 
the ECM bound TGFβ-LAP complex mechanically, releasing active TGF-β in a protease independent 
manner [57]. αvβ8 on lung fibroblasts has been suggested to take part in lung fibrosis, via a 
mechanism involving TGF-β activation by myofibroblasts [58]. Hinz has recently elegantly 
demonstrated that stiffness of the ECM can sensitize TGF-β to activation [59].  The importance of β1 
integrin function for TGF-β signaling was also underlined by the phenotype of mice lacking the β1 
integrin associated protein integrin-linked kinase (ILK) in fibroblasts [60]. In these mice, myofibroblast 
differentiation was severely impaired, corresponding to defective TGF-β signaling. 
 
Interesting candidates for mediating these effects in dermal fibroblasts are αvβ1 and α11β1. Elegant 
studies in mice trying to resolve the role of TGF-β activating integrins in fibrosis have demonstrated 
the fundamental role of  αv integrins on pericyte derived myofibroblasts in liver and 
fibroblasts/pericytes in the lung [56], and more detailed studies have  demonstrated  the αvβ1 integrin  
heterodimer to mediate the integrin dependent activation of TGF-β resulting in fibrosis in the lung and 
liver [22]. The reason for believing that α11β1 integrin might be important stems from a recent study 
demonstrating a role for this integrin in myofibroblast differentiation from dermal fibroblasts [41]. 
However, in contrast to the situation in wound healing and fibrosis, limited information is available on 
the role of TGF-β activating integrins in CAFs. It will be interesting to determine the role of integrin 
αvβ1 and α11β1 on CAFs in different tumour types. Whether αvβ1-dependent and α11β1-dependent 
CAF subpopulations contribute to tumour stroma and to the growth of these tumours will be 
important to assess.   
 
2.2 Integrin function and CAF differentiation 
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Until recently, the prevailing dogma was that once the tumour has reached a certain size and the 
tumour stroma is well established the major function of the stroma is to nurture and support the 
growth of the tumour [16]. This dogma has now been challenged [21, 61]. Irrespective of the role of 
the stroma, fibroblasts in the tumour stroma are most often activated; they are differentiated into 
myofibroblasts characterized by expression of EDA+ fibronectin and α-SMA [14, 17]. For differentiation 
of a variety of progenitors into myofibroblasts two processes are of major importance: TGF-β signaling 
and cell contraction accompanied by ECM reorganization [62]. Integrins are important for both of 
these functions. The source of the fibroblasts most likely has bearing on the integrin repertoire of 
activated fibroblasts. In mouse skin wounds, as much as 30% of the myofibroblast-like cells in skin 
wounds are estimated to be contributed by activated NG2 proteoglycan-positive pericytes [63].  Other 
studies have recently via cell lineage tracing identified papillary dermal- and reticular dermal- 
fibroblasts with distinct biomarker profiles [64, 65]. It is currently unknown how these fibroblasts 
populations contribute to the CAF-rich stroma in subcutaneously grown tumours.  
 
2.3. CAF integrins and tumour cell proliferation 
A number of autocrine and paracrine loops exist in the tumour microenvironment, influencing directly 
or indirectly tumour growth. These have been reviewed in depth [66-68] elsewhere. Integrin function 
during these processes in CAFs might be to synergize with growth factor signaling pathways, but also 
to activate TGF-β. We have mentioned that the α11β1 is involved in paracrine signaling [47], but more 
examples of this modus operandi are likely to exist. In addition to these two central loops maintaining 
the activated state of CAFs, other paracrine mechanisms affecting the tumour cells or tumour 
angiogenesis are active. An example of this is the bi-directional PDGF-CC secreted by tumour, which 
has been shown to recruit PDGF αR-positive fibroblasts and to affect FGF-2 and FGF-7 synthesis by 
CAFs, in turn affecting tumour angiogenesis [69].  
 
2.4. CAF integrins and tumour stiffness 
Several studies suggest that the mechanical stiffness of the matrix is a major determinant of tumour 
growth [18, 19]. One role of the CAFs in this context is suggested to be to reorganize the matrix and to 
facilitate increased crosslinking of the fibrillar collagen matrix. Integrin-dependent MMP activity is 
likely to be involved as well as integrin-mediated contractile force. The close association between 
external and internal force in the context of tumour stroma has recently been highlighted in a study of 
squamous carcinomas [70]. A recent study documented a correlation between integrin α11 expression 
and LOXL1 activity in the tumour stroma [71].  This is interesting in relation to breast, colon and 
 8 
pancreatic cancer models where increased LOX levels and activity was associated with tumour 
metastasis [72-73].  
 
A second role of matrix stiffness might be to regulate TGF-β activation on CAFs. It is very likely that the 
CAFs have a central role in the TGF-β activation in the tumour stroma. Recent elegant studies have 
shown how a stiff matrix sensitizes the TGF-β-LAP complex for activation [59, 74]. However, the role of 
specific integrin heterodimers in this process remains to be determined.  
 
2.5. Integrin function in CAF-promoted invasion and metastasis  
Revealing in vitro studies have shown that integrins on contractile CAFs are an integrated part of 
tunneling of the matrix, paving the way for invading tumour cells [70, 75]. A tissue-, tumour-and stage-
specific induction of different MMPs accompanies this process. Some of the molecular details for these 
processes have been elucidated and shown to include RhoA, Rab21 and YAP [70, 76-78].  In an 
experimental 3D system in vitro human CAFs from ovarian carcinomas were found to express αv 
integrins and a limited set of β1 integrins [76]. In the same experimental system only the α3β1 and 
α5β1 integrins were found to mediate CAF migration through a complex matrix composed of collagen I 
and a laminin -111 enriched matrix. In the future it will be important to determine if collective and 
single cell migration involves similar mechanisms of dissemination and to what degree an active CAF 
phenotype is needed for the proteolytic activity. Recent data suggest that primary tumour cells bring 
along CAFs to the new metastatic site [79]. In terms of the soil and seed terminology, the tumour cells 
bring their soil along. This might serve to condition the new environment for the future expansion of 
the tumour cells. 
 
In summary, integrins in the CAF context are likely to be key players in matrix synthesis, remodeling, 
degradation, stiffness regulation, TGF-β activation and invasion mediators. Selectively targeting these 
activities might be a more controllable path to cancer therapy, in concert with other strategies 
directed to the tumour cells themselves.  
 
 
3. Discoidin Domain Receptors 
 
The discoidin domain receptors (DDRs) are receptor tyrosine kinases (RTKs) that function as collagen 
receptors [80, 81]. There are two closely related receptors in this RTK subfamily: DDR1 and DDR2. The 
DDRs are the only RTKs that interact with structural components of ECMs and are thus key players at 
the interface between RTKs and matrix receptors. The DDRs are characterised by the presence of a 
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name-giving discoidin homology (DS) domain in their extracellular regions followed by a tightly linked 
domain of similar structure: the discoidin-like (DS-like) domain (Figure 2) [82]. Both DDRs are widely 
expressed in different tissues, throughout development and in adult organisms [81]. DDR1 is mainly 
found in epithelial cells while DDR2 expression predominates in connective tissues that originate from 
embryonic mesoderm. In addition, the DDRs are also present in immune cells. 
  
While the DDRs fulfil important roles in embryo development (DDR1 being essential for murine 
mammary gland development and DDR2 for bone growth in mice and humans), their functions in adult 
tissues are less well defined [81]. At the cellular level, the DDRs control fundamental processes, 
including cell proliferation, differentiation, migration and survival, which are typically regulated by 
RTKs. In addition, they contribute to ECM remodelling by controlling the expression and activity of 
matrix metalloproteinases. Dysregulation of DDR function and/or expression contributes to disease 
progression of a wide variety of human disorders, including organ fibrosis, arthritis and a long list of 
cancers [81, 83, 84]. Both DDRs are considered valid therapeutic targets, but mechanistic insight into 
their roles in various diseases is largely at an early stage. 
 
3.1. DDR Signalling 
Among RTKs, the DDRs have a unique mechanism of activation which is as yet not fully characterised. 
The DDRs bind to a number of different collagen types, with fibril-forming collagens acting as ligands 
for both DDR1 and DDR2 [85, 86]. Other collagens have distinct DDR binding preferences, such as the 
basement membrane collagen type IV, which binds only to DDR1, not DDR2 [85-87]. The DDR binding 
mode to fibrillar collagens is known at atomic detail. Both DDRs bind with high affinity to a six amino 
acid motif, GVMGFO (O is hydroxyproline), within collagens I, II and III [88, 89]. This motif is 
accommodated in a trench formed by several conserved surface-exposed loops at the ‘top’ of the DS 
domain, with all key collagen binding residues conserved between DDR1 and DDR2 [90, 91]. However, 
how collagen binding to the extracellular DS domains induces intracellular kinase activation is not 
known. In contrast to most other RTKs, which are thought to be present as monomers in the absence 
of ligand and to dimerise upon ligand binding [92], the DDRs are constitutive dimers [93-95]. 
Therefore, the model of ligand-induced receptor dimerisation does not apply to the DDRs. In addition, 
collagen-induced DDR phosphorylation occurs with protracted kinetics. Typical RTKs respond to ligand 
binding by autophosphorylation of cytoplasmic tyrosine residues within seconds to minutes, but this 
process is delayed for the DDRs and occurs in the timeframe of hours [85, 86]. At present, the cellular 
mechanisms behind the slow phosphorylation reaction are unknown. Collagen-induced DDR 
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phosphorylation is also sustained for many hours, but we do not understand the triggers that switch 
off DDR-induced signalling. 
 
Ligand binding of RTKs induces phosphorylation of distinct tyrosine residues that serve as docking sites 
for the recruitment of signalling proteins [92]. For the DDRs, only a handful of direct signalling partners 
have been identified, including the adaptors ShcA for both DDR1 and DDR2 [85, 96] and Nck2 for DDR1 
[97]. Other molecules known to interact with phosphorylated DDR1 include the phosphatases SHP-1 
[98] and SHP-2 [97, 99] and members of the Stat family of transcription activators [99, 100]. For DDR2, 
downstream effectors include SHP-2, Nck1, the Src family kinase Lyn and phospholipase C-like 2 [101], 
but it is not known whether any of these interact directly with the activated receptor.  
 
The DDRs initiate different signalling pathways depending on the cell type and context. For example, 
DDR-activated MAP kinase signalling can occur via distinct MAP kinase family members. In smooth 
muscle, mammary epithelial and megakaryocytes, DDR1 activates ERK1/2 [98, 102, 103], while in 
mesangial cells ERK1/2 is repressed by DDR1 [104]. DDR1 can also activate JNK in adipose stromal cells 
[105]. DDR2 signals to ERK1/2 and p38, but not JNK, in chondrocytes [106] but uses p38 and JNK, and 
not ERK1/2, in transfected embryonic kidney cells [107]. In osteoblasts, DDR2 signalling activates the 
transcription factor Runx 2, but conflicting data exist whether this is via p38 MAP kinase or ERK1/2 
[108, 109]. 
 
3.2. DDRs and Cancer 
Many cancers are characterised by aberrant expression or activities of one or more RTKs, whose 
dysregulated function can directly contribute to disease progression. It is therefore not surprising that 
altered DDR expression is found in cancer. Aberrant DDR signalling is thought to contribute to 
malignancy of a wide range of cancers, including solid tumours as well as blood cancers. The list ranges 
from breast, lung, brain, ovarian, prostate, head and neck, liver and pancreatic cancer, to lymphomas 
and leukaemias [83]. A number of studies have shown that dysregulated DDR expression correlates 
with unfavourable outcomes for patients, and there are active drug development programmes that 
target the DDRs in various cancers. The roles that the DDRs play in malignancy are likely to be 
multifaceted, as several distinct functions have emerged. For instance, DDR1 can control cell invasion, 
collective cell migration, metastasis, resistance to chemotherapy and mediate pro-survival signals [83, 
110-113]. Furthermore, it may be involved in the recurrence of certain types of cancer [114]. DDR2 is 
likewise important in mediating metastasis [115] and may be an oncogenic driver in lung cancer [116]. 
How the DDRs regulate various steps of cancer progression is not well understood, but it is believed to 
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be at least partly through their ability to regulate the interactions of cancer cells with collagen. 
Therefore, the normal cellular functions of the DDRs that regulate cell proliferation, tissue 
morphogenesis and cell differentiation may be hijacked by tumour cells, resulting in pro-migratory and 
pro-invasive phenotypes. This is in keeping with DDR overexpression in highly aggressive cancers, such 
as gliomas [117] or invasive breast carcinomas (see below).  
 
While other RTKs often contribute to cancer progression through oncogenic receptor mutations that 
result in altered receptor function, the evidence for somatic DDR mutations acting as oncogenic driver 
mutations is less clear. For example, several DDR1 mutations were observed in non-small cell lung 
carcinoma (NSCLC) in one study [118] but these findings were not replicated in another study that 
specifically sought to identify somatic DDR mutations in NSCLC [119]. Somatic DDR mutations were 
also found in primary lung adenocarcinoma [120] but the functional significance of these mutations is 
not clear. A comprehensive study that analysed the entire kinome in squamous cell carcinoma (SCC) of 
the lung identified somatic DDR2 mutations in about 4% of tumour samples and cell lines [116]. 
However, the mutations were not restricted to a particular region in the DDR2 gene and affected both 
the receptor’s globular domains and its juxtamembrane regions. Some of these DDR2 missense 
mutations seemed to result in an oncogenic gain of function phenotype in vitro, and SCC lines 
harbouring these mutations were selectively killed by DDR2 knockdown or treatment with dasatinib, a 
multi-kinase inhibitor [116]. Furthermore, a patient with lung SCC who harboured a DDR2 kinase 
mutation, but did not have any EGF receptor mutations, responded to a combination of dasatinib and 
erlotinib (an inhibitor of EGF receptor) treatment, which provided a rationale for clinical use of DDR2 
kinase inhibitors [116]. This is backed up by another report on a lung SCC patient who responded to 
dasatinib treatment and was found to have the same DDR2 kinase mutation [121]. The initial study 
concluded that gain of functions mutations in DDR2 are oncogenic and provided the first targetable 
mutations in lung SCC [116] and hence caused much excitement in the field. However, the study did 
not address the contribution of wild-type DDR2 to oncogenesis, and while several more recent studies 
have confirmed the occurrence of DDR2 mutations in different patient populations [122-124], it is far 
from clear whether the mutations are indeed oncogenic and their roles in lung SCC cell signalling are 
undefined [125]. Notably, in other studies, some of the ‘oncogenic’ DDR2 mutants either seemed to 
play tumour suppressive functions [101], or did not contribute to cell proliferation in lung SCC cell lines 
[126]. 
 
3.2.1. DDR1 and lung cancer 
Notwithstanding the unclear role of DDR1 mutations, there is good evidence that DDR1 plays an 
important role in tumour progression and metastasis of lung cancer. Overexpression of DDR1 in 
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tumour tissue, relative to normal lung tissue, was found in several studies and was associated with 
poor patient prognosis in all but one report [111, 119, 127, 128]. Furthermore, DDR1 mediated cell 
migration and invasion of NSCLC cell lines in vitro [127, 128], as well as cell survival, homing and 
colonization in a mouse model for lung cancer metastasis to the bone [111]. DDR1 therefore appears 
to be a promising molecular target for NSCLC patients with bone metastasis, and it is hoped that its 
inhibition, together with chemotherapy, may provide clinical benefits. In a phosphoproteomic 
approach, DDR1 was found to be amongst the most highly phosphorylated RTKs in a set of 150 NSCLC 
tumour samples [129], and is thus a candidate molecule for an oncogenic driver kinase. However, the 
relevance of these findings for lung cancer patients needs to be addressed in further studies. 
Interestingly, a recent study found lung cancer to be promoted by the minor collagen type IV α5 chain, 
which has restricted tissue distribution and is highly expressed in lung tissue [130]. In a mouse model, 
where cancer onset is driven by KRasG12D, collagen α5 (IV) was indispensable for cancer progression, via 
its interactions with DDR1, which resulted in downstream ERK activation [130]. Therefore, DDR1-
mediated carcinoma cell interactions with the matrix can play a key role in lung cancer progression. 
 
3.2.2. DDRs, Breast Cancer and Epithelial-Mesenchymal Transition 
Collagen plays an important role in breast cancer development and disease progression. Collagen-
dense stroma results in higher tissue density, which is associated with increased breast cancer risk. 
Dysregulated DDR expression is linked to breast cancer patient survival, although the picture is less 
straightforward than in lung cancer. In normal breast tissue, DDR1 is expressed in epithelial cells and 
required for mammary gland function [100, 131]. DDR2 expression, on the other hand, is absent [115]. 
In invasive breast cancer cell lines, but not in non-invasive cells, DDR1 transcription is negatively 
regulated by the transcription factor ZEB1 during epithelial-mesenchymal transition (EMT) [132]. Early 
work on breast carcinoma suggested DDR1 mRNA is abundant in invasive carcinoma and lymph node 
metastasis [133] but later studies found reduced DDR1 mRNA and protein in various types of breast 
carcinomas, with somewhat conflicting results as to which type of tumour was affected by altered 
DDR1 expression [134, 135]. More recent work has shown that while DDR1 is reduced in tumour 
tissue, DDR2 expression is upregulated, and that DDR2 expression may define a particularly aggressive 
subset of breast cancers [136]. Increased DDR2 expression was also linked to poor patient survival in 
another study [115]. A comprehensive study on DDR expression in invasive breast carcinoma analysed 
DDR1 and DDR2 expression by immunohistochemistry [137]. While there was no significant association 
between DDR1 expression level and patient outcome, DDR2 expression correlated with worse survival. 
In particular, a profile of high DDR2/low DDR1 expression in invasive carcinoma of the triple-negative 
subtype was associated with poor patient outcome. Therefore, this DDR expression profile may help to 
identify invasive carcinomas with poor prognosis.  
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The molecular mechanism by which DDR2 mediates breast cancer metastasis has been uncovered in a 
study using invasive breast cancer cell lines [115]. It was found that collagen type I activates DDR2, 
which in turn mediates ERK2 activation in a Src-dependent manner. This results in phosphorylation of 
SNAIL1, a transcription factor that mediates EMT. Phosphorylated SNAIL1 accumulates in the nucleus 
where it is protected from ubiquitination and subsequent proteasomal degradation. Thus, DDR2 
stabilises SNAIL1, which was shown to be crucial for breast cancer invasion and migration in vitro, as 
well as metastasis in vivo. The results of this study, in combination with the reports on increased DDR2 
expression being linked to poor patient prognosis [115, 136, 137], indicate that DDR2 may be a valid 
drug target for treatment of breast cancer metastasis. 
 
3.2.3. Prospects for DDR-based Therapy 
Other studies also indicate the DDRs as promising targets for anticancer therapy of metastatic cancer 
(e.g. DDR2 in metastatic melanoma [138, 139]). Since dysregulated DDR activity is often associated 
with particularly aggressive forms of cancers that currently lack targeted treatment options, the 
development of DDR-selective inhibitors may be a promising therapeutic avenue for rational cancer 
treatment.  A sharp increase in research related to the development of DDR kinase inhibitors reflects 
this thinking [140-142]. Inhibitors originally developed to target the activity of BCR-ABL kinase are also 
potent inhibitors of the DDRs [143, 144], but these drugs have a very broad specificity and are active 
against a number of additional kinases. Orally bioavailable small molecule kinase inhibitors with 
selectivity over other kinases have been developed for DDR1 and DDR2 [126, 145-147]. However, since 
kinase-independent functions have been discovered for DDR1, in particular its essential role in 
collective cancer cell migration and invasion [110], DDR-selective kinase inhibitors may not be effective 
against all DDR-dependent roles in disease progression. Alternative strategies could be based on 
allosteric sites in the DDR ectodomain, such as function-blocking antibodies that target DDR1 [82]. A 
further limitation of using single agent DDR selective kinase inhibitors may be related to a general 
problem of kinase inhibitors in cancer treatment: cancer therapies based on selective kinase targeting 
often fail eventually when tumour cells become treatment resistant. Recent studies have analysed the 
mechanisms of drug resistance and found that targeted kinase inhibition can lead to kinome 
reprogramming. For instance, treatment of breast cancer cells with inhibitors of the non-receptor 
kinase MEK or the RTK ErbB2 showed rapid reprogramming through induced expression and activation 
of multiple RTKs (including DDR1) and non-receptor kinases, which mediate growth and survival, thus 
bypassing the initial inhibition [148, 149]. Future therapeutic strategies will need to identify effective 
combination therapies or combining kinase inhibitors with inhibitors that block treatment-induced 
kinome adaptation [149]. 
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4. Cell Surface Proteoglycans 
 
Proteoglycans, by definition, consist of a core protein to which one or more glycosaminoglycan chains 
are covalently attached. There are only a few types of glycosaminoglycans in mammals, these being 
hyaluronan (HA), chondroitin sulphate (CS) with its close relative dermatan sulphate (DS), heparan 
sulphate (HS) and keratan sulphate (KS). While HA can reach up to 2 x 106 Daltons, mostly, these 
polysaccharides consist of around 50-150 repeating disaccharides [150]. Hyaluronan or hyaluronic acid 
also consists of repeating disaccharides, but in this case is synthesized at, and directly exported from, 
cell surface synthases [151]. As a result of this unique synthetic pathway, HA is not sulfated or 
attached to a core protein at synthesis, though it may be cross-linked to proteins in the ECM [152]. HA 
is recognized as being a particularly important ECM component with respect to tumour biology [153]. 
The sulphated glycosaminoglycans are among the most complex polysaccharides of bilaterian animals, 
in large part resulting from the extent and location of sulfate groups along the chain. There have been 
several recent reviews covering aspects of glycosaminoglycan synthesis, structure and interactions 
[154-156]. 
 
4.1 The Classes of Cell Surface Proteoglycans 
There are two major classes of cell surface proteoglycan, the glypicans and the syndecans, both with a 
long evolutionary history. The former are attached to the cell membrane through a phospholipid 
anchor [157], and are therefore not transmembrane. Moreover, while their heparan sulfate chains (HS) 
and core proteins interact with, and are important co-receptors for, a number of growth factors and 
morphogens, they do not appear to have a significant role in cell-ECM interactions, and are not 
considered further here. Information on these proteoglycans, of which there are six in mammals, can 
be found elsewhere [157, 158]. The syndecans are transmembrane proteoglycans, and are present in 
almost all nucleated cells of mammals. They therefore have the potential to signal and data is now 
becoming available on how this is achieved. All syndecans bear glycosaminoglycan chains, usually HS, 
through which interactions with numerous ligands is achieved, including many ECM molecules. It is an 
important facet of ECM collagens and glycoproteins, that most possess heparin (or HS)-binding motifs, 
which facilitate interactions with syndecans. These motifs, although generally being cationic, may vary 
greatly, when comparing say fibronectin, tenascin and interstitial collagens, and have varying affinity. 
Likely therefore, these motifs have arisen as a result of convergent evolution [159].  
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ECM macromolecules with heparin-binding properties are found in all types of matrices. Glycoproteins 
such as fibronectin, fibrinogen and von Willebrand Factor are important in wound repair mechanisms 
and can be derived from the circulation [160]. Others, such as the matricellular proteins including 
tenascins, thrombospondins and Cyr61/CTGF/NOV (CCN) proteins are also expressed in response to 
tissue damage or disease, including tumours [161, 162]. On the other hand, more stable fibril-
associated glycoproteins such as fibrillin-1 has heparin-binding motifs that function in combination 
with integrin-binding motifs to support cell adhesion [163]. In the case of fibrillin-1 and fibronectin, 
heparin-binding and integrin-binding motifs are separate yet adjacent [160, 163, 164] allowing ternary 
complexes of syndecan, integrin and ECM molecule to form, although integrins themselves are not 
heparin-binding. This is best characterised with respect to fibronectin, where the crystal structures of 
the integrin-binding site in repeat III10 and the HepII domain (repeats III12-14) have been solved [165, 
166] and the receptor binding and cell adhesion events associated with them have been well 
characterised [164-168]. These ternary complexes may be involved in cell-ECM junction assembly (e.g. 
focal adhesions). While many ECM glycoproteins contain heparin (or HS)- binding motifs, so do many 
collagens, both fibrillary and non-fibrillar, and several enzymes responsible for matrix turnover are also 
potentially proteoglycan-binding, e.g. MMP2 and 7, ADAM12 and ADAMTS4 [159, 169-172]. However, 
the functions of syndecan interaction with metalloproteinases are not yet well understood [173]. 
 
In addition to the four syndecans of mammals, there are a small number of unrelated transmembrane 
proteoglycans, some of which interact specifically with ECM components. The NG2/CSPG4 large 
proteoglycan has a single CS/DS chain, and can interact with type VI collagen, for example [174]. It is a 
marker of vascular mural cells, and is highly upregulated in melanoma, where it may contribute to 
invasive behaviour. The mechanisms involve activation of RTKs with sustained ERK1,2 signalling, and 
integrins [175]. This theme is common to other cell surface proteoglycans, e.g. CD44 and syndecans.  
In soft tissue sarcoma patients, enhanced CSPG4 expression (with up-regulated collagen VI) allows 
prognosis and stratification of patients, it being a predictor of metastasis [174].  
 
4.2 Common Themes in Cell Surface Proteoglycans 
Despite the lack of common core protein structure, there are some principles that unite the 
transmembrane proteoglycans. First, all connect with the actin cytoskeleton. This involves indirect 
linkage to actin rather than direct, through intermediates, notably members of the ezrin-radixin-
moesin family (ERM). In syndecans, this interaction occurs through a highly conserved juxtamembrane 
region of the cytoplasmic domain [176]. Similar interactions are noted with CD44 [177]. In the case of 
syndecan-4, a widespread member of the family and moreover, the only cell surface proteoglycan 
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encountered in focal adhesions, there are additional interactions with α-actinin [178]. This interaction 
appears important for linking syndecans to microfilament bundles, and therefore of significance in the 
control of cell adhesion and migration. However, the actin cytoskeleton has many roles besides cell 
adhesion, including intracellular trafficking, cytokinesis and endocytosis/exocytosis [179]. Evidence 
from syndecan-1 suggests that ERM interactions can be important for receptor internalization [180] 
and clearance, as demonstrated in lipid metabolism [181]. 
 
A second common theme with cell surface proteoglycan C-termini is the interaction with PDZ proteins. 
This has been demonstrated in syndecans, CD44, NG2 and neuropilin 1 [167]and is not restricted to a 
single PDZ protein, though syntenin features most often. Other partners include synectin (GIPC and 
CASK [167]. Syntenin was previously known as mda-9 (melanoma differentiation-associated protein 9) 
with evidence for a supporting role in tumour progression [182]. Recent work also suggests that PDZ 
interactions have relevance to trafficking, perhaps routing proteoglycans to the cell surface [183]. In 
addition, however, there is interesting evidence to suggest that syntenin/syndecan in conjunction with 
the syntenin-binding protein ALIX is involved in, or can enhance, exosome production [184]. There is 
now much interest in the potential roles of exosome in tumour biology [185] and so a role for 
syndecan-syntenin in this process deserves further attention.  
 
4.3 CD44-specific signaling 
Some proteoglycans are sometime substituted with glycosaminoglycans, but at other times not, so 
they are often referred to as “part-time” proteoglycans. Prominent among these is CD44, a widespread 
receptor both for growth factors or cytokines as well as HA [186]. It possesses a canonical Ig motif 
through which interactions with HA take place, a motif that is shared with other ECM proteoglycans 
that form large aggregates with HA, such as aggrecan of cartilage, brain and other matrices [187]. 
CD44 has captured a great deal of interest with respect to tumour biology, since expression of some 
splice variants is strongly associated with tumour progression [188]. The CD44v6 variant can act as a 
co-receptor with vascular endothelial growth factor receptor or with c-Met, where the hepatocyte 
growth factor ligand binds both receptors [189]. Downstream signaling is complex in these cases, 
involving Ras-dependent signalling to survival and apoptosis resistance and to Rac-1 that can promote 
actin cytoskeletal organisation consistent with migration and invasion [190]. The CD44v6 isoform can 
also signal to the PI-3K/Akt pathway in response to ECM interactions [191]. In some cells, such as 
fibroblasts, CD44 is expressed bearing a single CS/DS chain, while the v3 splice variant contains a motif 
for HS substitution [192] that allows it to serve as a co-receptor for RTKs, e.g. FGFR [159]. Association 
of CD44 with LRP6 and Frizzled can enhance Wnt signaling with β-catenin activation and translocation 
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to the nucleus where it functions as a transcription factor [186]. There is also much interest in CD44 as 
a cancer stem cell marker, for example in colon, breast, prostate and pancreatic carcinomas [193]. 
 
Signaling responses to HA by CD44 appear to depend on HA size. High molecular weight HA can, in 
theory, cluster many CD44 receptors on the cell surface. In contrast, in disease or inflammatory states, 
HA can be cleaved by hyaluronidases or free radicals, generating small oligosaccharides. These in 
addition to CD44 receptors may also bind to TLR2 and 4 receptors, triggering innate immune responses 
[194]. CD44, in addition to binding ERM proteins can also indirectly govern the activation of Rho family 
GTPases, notably Rac1 and RhoA [189, 194]. This combination of linkage to, and regulation of, the actin 
cytoskeleton endows CD44 with cell adhesion receptor function, in this case to HA.  
 
4.4 Syndecan-specific signaling 
The short cytoplasmic domains of syndecans are quite conserved, and we have previously invoked a 
nomenclature for three small subdomains (Figure 1). The conserved membrane-proximal C1 region 
interacts with ERM proteins, while the C2 has PDZ-interacting properties. Neither region is therefore 
functionally unique, as these properties are present in other transmembrane proteoglycans. However, 
between these conserved regions is the V (variable) region, each syndecan having a distinct amino acid 
sequence. These V regions are, however, conserved across species, for example the V region of 
syndecan-1 is almost identical in rodents, pig, primates and avians. The V regions, however, have been 
reluctant to reveal their functions, with the possible exception of syndecan-4. Its unusual LGKKPIYKK 
amino acid sequence interacts with the phospholipid phosphatidylinositol 4,5 bisphosphate, which 
induces a conformational change in the syndecan [195]. This provides a platform for interaction and 
activation of protein kinase Cα [196]. There may be several substrates for the kinase, RhoGDI being 
one of them. This important regulator can sequester, but also target Rho family GTPases to specific 
intracellular sites [197]. Phosphorylation at serine34 triggers the release of GDP-Rho (but not GDP-Rac 
or GDP-cdc42) from RhoGDI, which can then be converted to the active GTP-Rho through one or more 
RhoGEFs, with downstream activation of targets such as Rho kinases, notably ROCK 1 [198, 199]. Other 
potential targets are p190RhoGAP, which may relocalise this Rho inactivator [200]. The net effect is 
promotion of stress fibres and focal adhesion formation, consistent with previous data suggesting a 
role for syndecan-4 in this process [164, 167]. 
 
Very recently, however, another potential substrate has been identified [201]. Evidence suggests that 
syndecans can regulate the canonical group of transient receptor potential calcium channels. A 
conserved serine residue [202] adjacent to the TRP domain of the channels can be phosphorylated in a 
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PKC-dependent manner, causing channel closure. Therefore, syndecan-4 null fibroblasts have higher 
resting cytoplasmic calcium levels than wild type counterparts, but removal of TRPC7 by siRNA causes 
calcium reduction, and concomitant stress fiber formation. Further evidence suggests this principle is 
common to all the syndecans, and we have shown that it is conserved in the invertebrate, C. elegans 
[201]. The channels may not interact directly with syndecan; in the case of syndecan-4, a complex with 
TRPC7 and α-actinin was observed. This is consistent with previous reports of direct interactions 
between this actin-associated protein and both syndecan-4 and TRPC6, a very close homolog of TRPC7 
[203]. Since calcium is a key regulator of many cellular processes, involving cytoskeletal and 
transcriptional regulation, it is possible that heparan sulfate-binding ligands can trigger common, 
localized calcium regulation through the syndecans with impact on the cell adhesion and migration 
phenotype. 
 
4.5 Syndecans and Cancer 
While there are few indications that syndecan mutations have a role in tumour progression, many 
studies have reported alterations in syndecan expression in solid and hematogenous tumours [173, 
204]. In most cases, however, it is unclear whether misexpressed syndecans are contributors or 
bystanders in tumour progression. However, in the case of myeloma, syndecan-1 expression has been 
causally related to tumour growth and malignancy [205]. In addition, there appears to be an important 
role for heparanase, an enzyme that cleaves heparan sulfate chains into oligosaccharides that may 
retain important biological functions  [205]. There are now several tumour types where heparanase is 
implicated in progression and an inhibitor is now in the early stages of clinical trials.  
 
In breast cancer, expression of syndecan-1 is related to poor prognosis, particularly where it is also 
present in the tumour stroma as well as carcinoma cells [206]. In a mouse model of mammary 
carcinogenesis, it was shown that syndecan-1 was required for Wnt1 promoted tumour formation 
[207]. This appears to be related to β–catenin/TCF signalling since syndecan-1 was shown to be 
essential for responsiveness to this important regulator of growth and proliferation [207].  However, in 
other tumour types, e.g. head/neck and oral squamous carcinomas, loss of syndecan-1 is related to a 
worse patient outcome. Cell surface syndecan-1 expression at the invasive front had a negative 
correlation with invasion depth of OSCC tumours. In addition, Farnedi A et al. [208] identified 
NG2/CSPG4 and syndecan-2 as unique relapse and overall survival prediction factors in head and neck 
cancer tumour patients. 
Clearly there is much to learn regarding syndecans’ roles in tumour biology, but likely, redundancy is 
an important issue. Mice null for syndecan-1, syndecan-4 or even both syndecan-1 and -4 are viable, 
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anatomically normal and fertile [201]. Single null mice have postnatal wound repair phenotypes, and 
the double null has alterations in early stages of epidermal differentiation [201], but overall, these 
phenotypes are mild. In contrast, deletion of enzymes involved in heparan sulfate synthesis can be 
severe or embryonic lethal. All this suggests redundancy, an issue that may complicate tumour studies. 
Only rarely are all four syndecans studied in a single patient sample. 
 
Another complication is that syndecans may not always function independently. Although not yet 
shown to be co-receptors with DDR proteins, they have been associated with integrins in many cases 
[168]. In epithelial cells, syndecan-1 has been reported to interact directly with αvβ3 and αvβ5 
integrins [209]. Moreover, large complexes containing syndecans and growth factor receptors may 
include integrins and possibly cell-cell adhesion molecules as well (e.g. VE-cadherin in endothelial cells 
– [210]). Syndecans may therefore aid in translating a growth factor signal into an adhesion response. 
The region of syndecan-1 ectodomain that interacts with integrins (known as synstatin) can be 
biologically important, notably in a cancer context. Beauvais et al. [210] showed in human mammary 
carcinoma cells that synstatin could be a powerful inhibitor. This raises the possibility of new 
approaches to target tumour cell surface receptors. This may apply to all the human syndecans. 
Syndecan-2 may regulate β1 integrin indirectly through its ectodomain interaction with CD148, a 
transmembrane phosphatase [211]. Syndecan-4 associates with integrins at focal adhesions, and 
influences the size and number of adhesions, with implications for cell migration [167]. 
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Figure legends 
 
Figure 1. Diagrams of Integrin, CD44, Syndecan and Discoidin Domain Receptors topography. All are 
transmembrane receptors for ECM molecules, despite quite different structures and modes of ligand 
binding. 
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Figure 2. Structural organisation of the DDRs. The extracellular regions are composed of an N-terminal 
discoidin homology (DS) domain, a DS-like domain and a juxtamembrane (JM) region. The DDR1 JM 
region contains ~50 amino acids, the DDR2 JM region has 30 amino acids. The transmembrane 
domains (TM) are followed by a large intracellular JM region (up to 170 amino acids in DDR1, ~140 
amino acids in DDR2) and a C-terminal kinase domain. The plasma membrane is represented by a grey 
bar. The collagen binding region in the DS domain is indicated in red. Several isoforms of DDR1 exist, 
which differ in their cytoplasmic regions. The two main isoforms, DDR1a and DDR1b, are shown. The 
DDR1b region with additional 37 amino acids in the intracellular JM region, relative to DDR1a, is 
highlighted in light grey.  
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LAP: latency associated peptide, CAF: Cancer-associated fibroblasts, NSCLC: non-small cell lung cancer, +, ++, +++ : approximate expression level, ? : not 
established 
 
Table 1. Integrin expression on different populations of differentiated fibroblasts. 
Integrin 
 
Ligands 
 
Myofibroblasts CAFs  References 
D1E1 collagens +, dermal fibroblasts (in vitro) ++, colon  [24, 35] 
D2E1 collagens +, dermal fibroblasts (in vitro) +, colon  [25, 35] 
D11E1 collagens +++, corneal fibroblasts, dermal fibroblasts (in vitro) ++, NSCLC  [26, 43, 47] 
D3E1 laminins  ++, head- and neck, vulva  [75] 
D5E1 fibronectin  ++, head- and neck, vulva, colon   [35,75] 
D4E7 fibronectin EDA,  VCAM-1, and more +, lung ?  [27] 
D8E1 fibronectin, vitronectin,  and more ++, heart, lung, liver ?  [28, 29] 
D9E1 
fibronectin EDA, tenascin-
C, emilin-1,  
and more  
+, skin ?  [30, 31] 
DvE1 vitronectin, fibronectin LAP +++, liver, lung ?  [22] 
DvE3 vitronectin, fibronectin, LAP +, dermal fibroblasts (in vitro) ?  [26] 
DvE5 vitronectin, fibronectin, LAP ++, dermal fibroblasts (in vitro) ++, NSCLC, colon  [32] 
DvE8 vitronectin, fibronectin, LAP ++,  dermal fibroblasts (in vitro) ?  [33] 
Table
